MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Entry into a Material Definitive Agreement

MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

On January 18, 2019, the Company entered into a securities purchase agreement (the SPA) with six purchasers (the Purchasers) to which the six Purchasers invested in the Company an aggregate amount of $2,900,000 in exchange for fifty eight (58) units (the Units), each consisting of a convertible note (the Convertible Note) with the principal amount of $50,000 and a warrant (the Warrant) to purchase common stock (the Common Stock) of the Company. to this SPA, the Company offered a minimum of $1,000,000 and a maximum of $6,000,000 (the Maximum Amount) of Units at a price of $50,000 per Unit until the earlier of i) the closing of the subscription of the Maximum Amount and ii) February 28, 2019 (the Termination Date), subject to the Companys earlier termination at its discretion. The SPA includes the customary representations and warranties from the Company and purchasers. Each Convertible Note offered by the Company as part of the Unit bears an interest rate of 12% per annum, has a principal amount of $50,000, shall mature in one year from the original issue date on January 18, 2019, and will be convertible into shares of Common Stock at a price of $0.40 subject to adjustment stated in the Convertible Note. to the terms of the Convertible Note, each holder of the Convertible Notes shall not own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock issuable upon exercise of such Convertible Note. Upon default, the penalty interest rate of the Convertible Note shall rise to 18% per annum. In addition, to the SPA, the Company offers, as part of the Unit, Warrants to purchase the Common Stock at a price of $0.75 per share (the Exercise Price), subject to adjustments stated therein. The holder of each Warrant may purchase the number of shares of Common Stock equal to the number of shares of Common Stock issuable upon conversion of each Convertible Note while the Warrant is exercisable. The Warrants have a term of three years and shall be exercised in cash or on a cashless basis as described in the Warrant.

The foregoing description of the APA Amendment, Assignment and Assumption Agreement, Voting Agreement, SPA, Convertible Note, and Warrant is qualified in its entirety by reference to the respective agreements, a copy of which are incorporated by conformed to the Current Report on Form 8-K dated January 14, 2019 and are hereby incorporated by reference into this Item 1.01.

Item 3.02 Unregistered Sales of Equity Securities

As described in Section 1.01 hereof, from January 17, 2019 to January 25, 2019, the Company issued convertible notes with an aggregate principal amount of $2,900,000 and Warrants, together constituting the Units, to the SPA.

Item 9.01 Financial Statements and Exhibits

N/A

Form of Warrant (Incorporated by reference from the Current Report on Form 8-K dated January 14, 2019).

An ad to help with our costs